Search

Displaying results 1661 - 1670 of 7479 in total
  1. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  2. Drug

    Metyrapone

    go.drugbank.com/drugs/DB01011
    ApprovedInvestigational

    An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.

  3. Drug

    Remifentanil

    go.drugbank.com/drugs/DB00899
    ApprovedInvestigational

    Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia. … Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic.

  4. Drug

    Sebetralstat

    go.drugbank.com/drugs/DB18305
    ApprovedInvestigational

    Hereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat [L53533

  5. Drug

    Tranylcypromine

    go.drugbank.com/drugs/DB00752
    ApprovedInvestigational

    An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).

    Synonyms: dl-tranylcypromine, trans-DL-2-Phenylcyclopropylamine
  6. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.

  7. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

  8. Drug

    Equine Botulinum Neurotoxin B Immune FAB2

    go.drugbank.com/drugs/DB13903
    Approved

    Equine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B. It is intravenously administered for the treat...

  9. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.

  10. Drug

    Papaverine

    go.drugbank.com/drugs/DB01113
    ApprovedInvestigational

    An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. … The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.